Welcome to our dedicated page for Biohaven Ltd. news (Ticker: BHVN), a resource for investors and traders seeking the latest updates and insights on Biohaven Ltd. stock.
Biohaven Ltd. (NYSE: BHVN) is a leading clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of transformative treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Leveraging multiple proprietary drug development platforms, Biohaven is advancing an impressive product pipeline that addresses a variety of diseases, ranging from neuromuscular and metabolic disorders to antibody-drug conjugates for cancer and obsessive-compulsive disorder.
Biohaven's notable product candidates include:
- Glutamate Modulation: Troriluzole, currently in Phase 3 trials for obsessive-compulsive disorder, offers hope for patients with inadequate responses to standard treatments.
- Myostatin Inhibition: Taldefgrobep alfa, in Phase 3 studies for spinal muscular atrophy and being evaluated for obesity treatment, targets muscle growth regulation pathways.
- Ion Channels: BHV-7000, a selective activator of Kv7.2/7.3 potassium channels, is in clinical development for epilepsy and mood disorders.
- Inflammation & Immunology: BHV-1300 and BHV-1310, from the innovative extracellular protein degradation platform, aim to treat autoimmune diseases by lowering IgG levels.
- Oncology: BHV-1510, a Trophoblast Cell Surface Antigen-2 (Trop-2) directed ADC, shows promise in treating select advanced epithelial tumors.
Recent milestones highlighted at the 42nd Annual J.P. Morgan Healthcare Conference and other events include significant progress in these areas and the initiation of pivotal human studies. CEO Dr. Vlad Coric emphasized the company's strong focus on neuroscience, immunology, and oncology, with near-term potential in these fields.
Financial updates reveal solid funding for future advancements, supported by a public offering that raised $230 million. Biohaven's robust clinical and preclinical pipelines are backed by an experienced leadership team and a strong financial foundation, underlining the company's capacity for rapid, efficient drug development.
The company’s leadership in neuroscience was underscored at the 2024 American Academy of Neurology Annual Meeting, featuring multiple presentations on Kv7 ion channel modulation, MoDEs, TRPM3 antagonism, and TYK2/JAK1 inhibition. Looking ahead, Biohaven is poised for a groundbreaking year, with multiple INDs planned and significant clinical data expected across its portfolio.
For more information, visit Biohaven's website.
Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) will report its second quarter 2021 financial results on August 9, 2021, at 8:30 a.m. ET. The earnings call will provide insights into the quarter ended June 30, 2021, along with a review of recent achievements and future milestones. Biohaven specializes in innovative therapies for neurological and neuropsychiatric diseases, including the FDA-approved NURTEC ODT for migraine treatment. Investors can access the call via phone or webcast through Biohaven's website.
Biohaven Pharmaceutical reported preliminary net product revenue of $93 million for NURTEC ODT in Q2 2021, surpassing expectations. Over 750,000 prescriptions have been filled since launch, showing robust growth. NURTEC ODT, the first dual-therapy migraine medication, is approved for both acute and preventive treatment. CEO Vlad Coric emphasized the medication's significant impact on patient care, while CCO BJ Jones highlighted positive feedback from clinicians and patients. The company anticipates continued growth in the migraine treatment market, benefiting approximately 40 million U.S. migraine sufferers.
Sosei Group Corporation announced the dosing of the first healthy subject with HTL0022562 (BHV3100) in a Phase 1 trial. This double-blind, placebo-controlled study will assess the safety and pharmacokinetics of the drug in 88 participants in the UK, expected to complete in 2022. This milestone marks the 10th drug candidate from Sosei's SBDD platform to enter clinical development. Under its collaboration with Biohaven, Sosei will receive milestone payments and funding for the trial while Biohaven leads future studies.
Biohaven Pharmaceutical (NYSE: BHVN) announces the appointment of Kishen Mehta to its Board of Directors. Mehta, a Portfolio Manager at Suvretta Capital, brings 15 years of experience in the financial industry and previously served as a strategic advisor to Biohaven. His expertise will support the company’s goal of becoming a leading biopharmaceutical entity. Biohaven continues to expand its CGRP migraine franchise and advance late-stage programs targeting neurological diseases. The company’s innovative portfolio includes FDA-approved NURTEC® ODT.
Biohaven Pharmaceuticals (NYSE: BHVN) celebrated the FDA approval of its migraine treatment by ringing the opening bell at the New York Stock Exchange on June 8, 2021. This event coincided with Migraine and Headache Awareness Month, highlighting the significance of their breakthrough medication, which is the first and only approved solution for treating and preventing migraines. The company aims to support the migraine community, reflecting its commitment to addressing this prevalent health issue.
Biohaven Pharmaceutical Holding Company (NYSE: BHVN) announced its participation in the 63rd Annual Scientific Meeting of the American Headache Society from June 3-6, 2021, showcasing 19 abstracts including a late-breaking presentation on Nurtec ODT (rimegepant). The FDA approved Nurtec ODT for preventive migraine treatment on May 27. Clinical data presented indicate a significant reduction in monthly migraine days and improved quality of life for patients, especially those who failed prior treatments. Additionally, a Phase 2/3 study of intranasal zavegepant demonstrated promising results for acute migraine treatment.
Biohaven Pharmaceutical announced the FDA approval of NURTEC® ODT (rimegepant 75 mg) for the preventive treatment of migraine, marking it as the first oral CGRP antagonist to receive such approval. This new label allows for up to 18 doses per month, offering both acute and preventive therapy. The approval significantly expands the market potential for NURTEC ODT, benefiting the approximately 95% of U.S. migraine patients with fewer than 15 headache days monthly. The medication's novel formulation provides flexible treatment options, covering a substantial unmet need in migraine care.
Biohaven Pharmaceuticals (NYSE:BHVN) announced that Nurtec® ODT (rimegepant) will be the primary partner for the Rick Ware Racing No. 51 NTT IndyCar Series program. This partnership aims to raise awareness for migraines, affecting nearly 40 million Americans. With Romain Grosjean as the driver, Nurtec ODT's branding will be showcased throughout the racing season. The company emphasizes the significance of addressing migraines, a debilitating condition, through strategic partnerships. Biohaven's commitment to innovation in migraine treatment is highlighted as they expand their outreach.
Biohaven Pharmaceutical (BHVN) reported first-quarter 2021 results, achieving net revenues of $43.8 million from NURTEC ODT, exceeding expectations. This figure marks a substantial increase from $1.2 million in Q1 2020. Despite a net loss of $261 million, the company highlighted significant advancements in its product pipeline, including progress on verdiperstat and zavegepant. The company aims to maintain momentum in the commercial growth of NURTEC ODT while pursuing regulatory submissions for new treatments.
FAQ
What is the current stock price of Biohaven Ltd. (BHVN)?
What is the market cap of Biohaven Ltd. (BHVN)?
What does Biohaven Ltd. specialize in?
What are some of Biohaven's key product candidates?
What recent milestones has Biohaven achieved?
How is Biohaven funded for its future projects?
What is Biohaven's approach to treating autoimmune diseases?
Where can I find more information about Biohaven's clinical trials?
Who leads Biohaven Ltd.?
What are the primary therapeutic areas Biohaven is focusing on in 2024?
What recent events highlight Biohaven's advancements in neuroscience?
How does Biohaven plan to use the funds from its recent offering?
